Abstract:Background PD-1/PD-L1 blockade is responsible for the majority of the success of cancer immunotherapy. 1 However, only 14% of patients eligible to receive checkpoint blockade achieve objected clinical responses. 2 3 The reason for the failure of PD-L1 blockade may be attributed to the recently appreciated widespread expression of PD-L2 across human cancers and its immunosuppresive stromal cells. 4 PD-L2 expression was shown to be as or more predictive of response to PD-1 blockade than PD-L14. PD-L2 traditionally was dismissed as functionally redundant to PD-L1 varying only in pattern of expression. We hypothesize that PD-L2 engages PD-1 to generate a distinct inhibitory signal from that of PD-L1, and antibody mediated blockade and depletion of PD-L2+ cells may promote anti-tumor immunity that is superior to PD-L1 blockade alone. Methods Cell based bioluminescent assay demonstrated the nature of regulation mediated by human PD-L2 through the PD-1 co-receptor. RNA-sequencing identified key differences in the signaling pathways generated in Jurkat T cells by PD-1 binding to PD-L1 or PD-L2. Multidimensional flow cytometry determined the differential effects of PD-L1 and PD-L2 on human T cell proliferation and effector function. Western blot elucidated the temporal kinetics of inhibition mediated by PD-L1 and PD-L2. Survival studies in murine syngeneic lymphoma model evaluated the efficacy of antibody mediated blockade and depletion of PD-L2+ cells. Results We validated that human PD-L2, unlike murine PD-L2, generates a purely co-inhibitory signal in human T cells, albeit with a reduced inhibitory potential relative to PD-L1. We discovered significant differences in downstream T cell signaling pathways generated by PD-L1 versus PD-L2 through PD-1 engagement. Human PD-L1 and PD-L2 differentially modulated T cell effector function and proliferation with PD-L2 preferentially arresting T cells in S-phase of cell cycle. PD-L1 and PD-L2 also differed in the temporal kinetics of dephosphorylation of the membrane proximal proteins in the TCR-CD3 signaling complex. We observed that combination blockade of PD-L1 and PD-L2 improves on blockade of PD-L1 alone resulting in increased production of IL-2 and IFNγ in primary human mixed lymphocyte reactions. Our data in a syngeneic murine model of EL4 showed that effector-function capable PD-L2 blocking antibodies are therapeutically superior to PD-L1 or PD-L2 blockade alone. Conclusions We are the first to report on T cell immunoregulatory functions of PD-L2 which are distinct from those of PD-L1, and demonstrate that the more tumor-selective expression pattern of PD-L2 relative to PD-L1 provides a therapeutic advantage to effector-function capable PD-L2 antibodies. Acknowledgements AS was supported by the CPRIT Research Training Grant(RP170067) References Ribas A, Wolchok JD (2018). Cancer immunotherapy using checkpoint blockade. Science 359 :1350–1355. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D (2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362 . Haslam A, Prasad V (2019). Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2 :e192535. Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE, McClanahan T (2017). PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 23 :3158–3167.

Deciphering Cholesterol's Role in PD-L2 Stability: A Distinct Regulatory Mechanism From PD-L1

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain

Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Programmed cell death-ligand 2: new insights in cancer

Genetically incorporated crosslinkers identify regulators of membrane protein PD-L1 in mammalian cells

Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling

New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle

The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation

Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy

Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells

Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy

PD-L2 Expression in Colorectal Cancer: Independent Prognostic Effect and Targetability by Deglycosylation.

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance

Computational analysis of PD-L1 dimerization mechanism induced by small molecules and potential dynamical properties

PD-1 regulation in immune homeostasis and immunotherapy

233 Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1